Catalent announces two appointments to executive leadership team in management realignment
Alessandro Maselli is to become its new Senior Vice President of Global Operations, and Christine Dolan will assume the role of Senior Vice President of Global Product Development.
Catalent Pharma Solutions has announced that Alessandro Maselli is to become its new Senior Vice President of Global Operations, while Christine Dolan will assume the role of Senior Vice President of Global Product Development.
Mr Maselli has extensive operations experience at several global organizations, and previously acted as Vice President Operations for Catalent’s Drug Delivery Solutions business in Europe. Prior to this, he was General Manager of Catalent’s Zydis orally disintegrating tablet facility in Swindon, UK, and held a number of other senior management and operational roles, having joined the organization from Alstom in 2010. Before joining Alstom, Mr Maselli had worked in business management and operations positions for SGS and ABB respectively.
He holds a master’s and bachelor’s degree in engineering from Università degli Studi di Roma 'La Sapienza,' Rome.
Mr Steve Leonard, who previously held the position, has decided to leave the company in early 2017, but will continue in an advisory position until that time, to assist with the transition.
Ms Dolan was appointed Vice President, Global Softgel Operations in November 2013, with responsibility for Catalent’s 11 Softgel manufacturing and development sites, spanning five continents. In this role she had operational responsibility for more than 3,500 employees.
She began her career with Catalent in 2009 in Global Quality, and in 2010 was named General Manager for Catalent’s Woodstock, Illinois, sterile technologies facility. She had previously acted as Vice President of Operations for the Development and Clinical Services Business Unit, with operational responsibilities for five of Catalent’s facilities providing clinical manufacturing, packaging, and analytical development of both large and small molecules. Following Catalent’s acquisition of Aptuit’s clinical trials business in 2011, Ms Dolan was named Vice President and General Manager of Development and Analytical Solutions, which included operations in Kansas City, Missouri, Morrisville, North Carolina, and Swindon, UK. Prior to Catalent, she worked as a microbiologist for Smith & Nephew Solopak, and also Amersham Health and GE Healthcare, where she served in various leadership roles.
Ms Dolan holds a bachelor’s degree in biology from Lenoir-Rhyne College, North Carolina.
“We are confident that both Alessandro and Christine will continue to drive the organization forward and believe that this management realignment will bring value, not only to Catalent as a business, but our customers, and ultimately patients,” commented John Chiminski, Catalent’s President and CEO. He added, “At the same time, it is important to recognize the enormous impact that Steve has made on the company’s transformation and growth since his appointment in 2009. We wish him all the best for the future and will always be appreciative of his professionalism, strategic contribution, energy and insight.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance